Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High vs Standard Dose Flu Vaccine in HSCT
NCT03179761Phase 2Completed
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Oct 2017
- Primary completion
- Feb 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of influenza vaccine in influenza (2 arms), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoint: Immunogenicity (Influenza A) - HAI Titer Rise or GMT. Started Oct 2017; status: completed.
02
Drugs
influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03179761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03179761.